Antibacterial drugs were first formulated in 1928 and have been used ever since. Antibacterial drugs are defined as substances that can inhibit or destroy the development and growth of bacteria. They are often called as antibiotics and are broadly utilized in the treatment and prevention of infectious diseases. A broad range of antibacterial drugs are available in the market which can be utilized in treating diseases such as tetanus, diarrhea, pneumonia, tuberculosis, and various other diseases.

Browse Full Report Global Antibacterial Drugs Market Research Report With Full TOC @ http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

The global antibacterial drugs market will decline at a -1.3% CAGR between 2015 and 2023. The market stood at US$43.9 billion in 2014 and is predicted to reach US$38.8 billion by 2023.

Antibacterial Drugs Market to Decline despite the Presence of Numerous Manufacturers

An increase in the number of generic drugs used in antibacterial treatment, reduced R&D, patent expiry, and rising market stagnancy are amongst the factors impeding the growth of the antibacterial drugs market.

However, a rising demand for affordable and effective antibacterial drugs, rise in aging population, presence of a large number of manufacturers in the market, and rising occurrence of infectious diseases are some of the factors fuelling the demand for antibacterial drugs. To add on, the predicted commercialization of numerous drugs that are at present in the development stage, namely VivaGel (SPL7013) (Starpharma Holdings Limited), solithromycin (Cempra, Inc.), MK-3415A (Merck & Co.), and surotomycin (Merck & Co.), could help counteract the negative market forces discussed above.

Β-Lactams Dominated the Market in 2014 with a Share of 57.7%

On the basis of class, the global antibacterial drugs market has been segmented into tetracyclines, macrolides, aminoglycosides, sulfonamides, β-lactams, phenicols, and miscellaneous antibacterials.

Among these, β-lactams are the most commonly utilized drugs and comprise all antibiotic agents that have a β-lactam ring inside their molecular structure. β-lactam antibiotics include cephamycins, penicillins, carbapenems, and cephalosporins. β-lactams dominated the market in 2014 by constituting a share of 57.7% in the overall market for antibacterial drugs.

Nonetheless, owing to key branded formulations’ looming patent expiry, along with the increasing count of bacterial strains that are drug resistant and rising influx of generic drugs, β-lactams are projected to experience a reduction in their market share in the forecast horizon. On the other hand, the segment for miscellaneous antibacterials is projected to witness the highest CAGR in the forecast horizon.

North American Antidrug Market Witnessed Sluggish Growth Owing to Strict Regulatory Requirements

The largest share in terms of revenue in the global antibacterial market was held by Asia Pacific and it is predicted to witness the most elevated growth rate in the forecast horizon. The factors responsible for fuelling the growth of the Asia Pacific market are increasing occurrence of bacterial infections, and the domestic population’s rise in purchasing power. After Asia Pacific, in 2014, North America emerged as the second biggest market on the basis of revenue in the antibacterial drugs market. However, the North American antidrug market witnessed lackluster growth owing to generic infiltration and strict regulatory requirements.

Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Allergen plc, Merck & Co., Inc., Johnson & Johnson Services, Inc., and Sanofi, and Novartis AG, Pfizer, Inc., are amongst the major players in the antibacterial drugs market.